Leukemia Research
Volume 33, Issue 11 , Pages 1485-1489 , November 2009

Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group

  • Martha Q. Lacy

      Affiliations

    • Mayo Clinic, Rochester, MN, United States
    • Corresponding Author InformationCorresponding author at: Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. Tel.: +1 507 284 8430; fax: +1 507 266 4972.
    • ,
  • Susanna Jacobus

      Affiliations

    • Dana Farber Cancer Institute, Boston, MA, United States
    • ,
  • Emily A. Blood

      Affiliations

    • Dana Farber Cancer Institute, Boston, MA, United States
    • ,
  • Neil E. Kay

      Affiliations

    • Mayo Clinic, Rochester, MN, United States
    • ,
  • S. Vincent Rajkumar

      Affiliations

    • Mayo Clinic, Rochester, MN, United States
    • ,
  • Philip R. Greipp

      Affiliations

    • Mayo Clinic, Rochester, MN, United States

Received 1 December 2008 ,Revised 1 December 2008 ,Accepted 18 January 2009.

References 

  1. Anonymous . Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group [see comments]. Annals of Internal Medicine. 1996;124(2):212–222
  2. The Myeloma Trialists’ Collaborative Group . Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. British Journal of Haematology. 2001;113(4):1020–1034
  3. Salmon SE, Crowley JJ, Balcerzak SP, et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology. 1998;16(3):890–896
  4. Ludwig H, Cohen AM, Polliack A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Annals of Oncology. 1995;6(5):467–476
  5. Shustik C. Interferon in the treatment of multiple myeloma. Cancer Control. 1998;5(3):226–234
  6. Browman GP, Bergsagel D, Sicheri D, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 1995;13(9):2354–2360
  7. Abrahamson GM, Bird JM, Newland AC, et al. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. British Journal of Haematology. 1996;94(4):659–664
  8. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108(10):3289–3294
  9. Martin M, Oken TL, Lenhard RE, Greipp PR, Kay NE, Van Ness B, et al. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma. Cancer. 1999;86(6):957–968
  10. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457–481
  11. Ansell SM, Geyer SM, Maurer MJ, et al. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Clinical Cancer Research. 2006;12(20):6056–6063[10.1158/1078-0432. CCR-06-1245]
  12. Ansell SM, Witzig TE, Kurtin PJ, et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002;99(1):67–74[10.1182/blood. V99.1.67]
  13. Pelloso D, Cyran K, Timmons L, Williams BT, Robertson MJ. Immunological consequences of interleukin 12 administration after autologous stem cell transplantation. Clinical Cancer Research. 2004;10(6):1935–1942[10.1158/1078-0432. CCR-03-1156]
  14. Hansson L, Abdalla AO, Moshfegh A, et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clinical Cancer Research. 2007;13(5):1503–1510[10.1158/1078-0432. CCR-06-1603]

☆ This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, M.D.) and supported in part by Public Health Service Grants CA23318, CA66636, CA21115, CA13650 and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

PII: S0145-2126(09)00027-7

doi: 10.1016/j.leukres.2009.01.020

Leukemia Research
Volume 33, Issue 11 , Pages 1485-1489 , November 2009

Article Tools

* Image Usage & Resolution